


[Claims]

1. A compound having the formula



- a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :
- p* represents an integer being 0, 1, 2, 3 or 4;
- X* represents O, S, NR⁵ or a direct bond;
- Y* represents O, S, NR⁵, or S(O)₂;
- each R¹ independently represents C₁-6alkyl, halo, polyhaloC₁-6alkyl, hydroxy, mercapto, C₁-6alkyloxy, C₁-6alkylthio, C₁-6alkylcarbonyloxy, aryl, cyano, nitro, Het³, R⁶, NR⁷R⁸ or C₁-4alkyl substituted with Het³, R⁶ or NR⁷R⁸;
- R² represents Het¹, C₃-7cycloalkyl, C₁-6alkyl or C₁-6alkyl substituted with one or two substituents selected from hydroxy, cyano, amino, mono- or di(C₁-4alkyl)amino, C₁-6alkyloxy, C₁-6alkylsulfonyloxy, C₁-6alkyloxycarbonyl, C₃-7cycloalkyl, aryl, aryloxy, arylthio, Het¹, Het¹oxy and Het¹thio; and if *X* is O, S or NR⁵, then R² may also represent aminocarbonyl, aminothiocarbonyl, C₁-4alkylcarbonyl, C₁-4alkylthiocarbonyl, arylcarbonyl, arylthiocarbonyl, Het¹carbonyl or Het¹thiocarbonyl;
- R³ represents hydrogen, C₁-6alkyl or C₃-7cycloalkyl;
- R⁴ represents hydrogen, C₁-6alkyl or C₃-7cycloalkyl; or
- R³ and R⁴ taken together form a C₂-6alkanediyl;
- R⁵ represents hydrogen or C₁-4alkyl;
- each R⁶ independently represents C₁-6alkylsulfonyl, aminosulfonyl, mono- or di-(C₁-4alkyl)aminosulfonyl, mono- or di(benzyl)aminosulfonyl, polyhaloC₁-6alkylsulfonyl, C₁-6alkylsulfinyl, phenylC₁-4alkylsulfonyl, piperazinylsulfonyl, aminopiperidinylsulfonyl, piperidinylaminosulfonyl, *N*-C₁-4alkyl-*N*-piperidinylaminosulfonyl or mono-or di(C₁-4alkyl)aminoC₁-4alkylsulfonyl;
- each R⁷ and each R⁸ are independently selected from hydrogen, C₁-4alkyl, hydroxy-C₁-4alkyl, dihydroxyC₁-4alkyl, aryl, arylC₁-4alkyl, C₁-4alkyloxyC₁-4alkyl, C₁-4alkylcarbonyl, aminocarbonyl, arylcarbonyl, Het³carbonyl, C₁-4alkylcarbonyloxy-C₁-4alkylcarbonyl, hydroxyC₁-4alkylcarbonyl, C₁-4alkyloxycarbonylcarbonyl, mono- or di(C₁-4alkyl)aminoC₁-4alkyl, arylaminocarbonyl, arylaminothiocarbonyl, Het³aminocarbonyl, Het³aminothiocarbonyl, C₃-7cycloalkyl, pyridinylC₁-4alkyl, C₁-4alkanediyl-C(=O)-O-R¹⁴, -C(=O)-O-R¹⁴, -Y-C₁-4alkanediyl-C(=O)-O-R¹⁴, Het³, Het⁴ and R⁶;

D²
cont

- 5 R^9 and R^{10} are each independently selected from hydrogen, C_{1-4} alkyl, hydroxy C_{1-4} alkyl, dihydroxy C_{1-4} alkyl, phenyl, phenyl C_{1-4} alkyl, C_{1-4} alkyloxy C_{1-4} alkyl, C_{1-4} alkylcarbonyl, aminocarbonyl, phenylcarbonyl, Het³carbonyl, C_{1-4} alkylcarbonyloxy C_{1-4} alkylcarbonyl, hydroxy C_{1-4} alkylcarbonyl, C_{1-4} alkyloxycarbonylcarbonyl, mono- or di(C_{1-4} alkyl)amino C_{1-4} alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, Het³aminocarbonyl, Het³aminothiocarbonyl, C_{3-7} cycloalkyl, pyridinyl C_{1-4} alkyl, C_{1-4} alkanediyl-C(=O)-O- R^{14} , -C(=O)-O- R^{14} , -Y- C_{1-4} alkanediyl-C(=O)-O- R^{14} , Het³, Het⁴ and R^6 ;
- 10 each R^{11} independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C_{1-4} alkyloxy, formyl, trihalo C_{1-4} alkylsulfonyloxy, R^6 , NR^7R^8 , C(=O) NR^7R^8 , -C(=O)-O- R^{14} , -Y- C_{1-4} alkanediyl-C(=O)-O- R^{14} , aryl, aryloxy, arylcarbonyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, phthalimide-2-yl, Het³ and C(=O)Het³;
- 15 R^{12} and R^{13} are each independently selected from hydrogen, C_{1-4} alkyl, hydroxy C_{1-4} alkyl, dihydroxy C_{1-4} alkyl, phenyl, phenyl C_{1-4} alkyl, C_{1-4} alkyloxy C_{1-4} alkyl, C_{1-4} alkylcarbonyl, phenylcarbonyl, C_{1-4} alkylcarbonyloxy C_{1-4} alkylcarbonyl, hydroxy C_{1-4} alkylcarbonyl, C_{1-4} alkyloxycarbonylcarbonyl, mono- or di(C_{1-4} alkyl)amino C_{1-4} alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, C_{3-7} cycloalkyl, pyridinyl C_{1-4} alkyl, C_{1-4} alkanediyl-C(=O)-O- R^{14} , -C(=O)-O- R^{14} , -Y- C_{1-4} alkanediyl-C(=O)-O- R^{14} and R^6 ;
- 20 each R^{14} independently represents hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, aminocarbonylmethylene or mono- or di(C_{1-4} alkyl)aminocarbonylmethylene; aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, cyano, halo, hydroxy, C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{1-4} alkyloxy, formyl, polyhalo C_{1-4} alkyl, NR^9R^{10} , C(=O) NR^9R^{10} , C(=O)-O-
- 25 R^{14} , R^6 , -O- R^6 , phenyl, Het³, C(=O)Het³ and C_{1-4} alkyl substituted with hydroxy, C_{1-4} alkyloxy, C(=O)-O- R^{14} , -Y- C_{1-4} alkanediyl-C(=O)-O- R^{14} , Het³ or NR^9R^{10} ;
- 30 Het¹ represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, 1H-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and
- 35 imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each

P2
cont

- independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with one or two substituents independently selected from Het² and R¹¹;
- Het² represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, 1H-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het⁴, R¹¹ and C₁₋₄alkyl optionally substituted with one or two substituents independently selected from Het⁴ and R¹¹;
- Het³ represents a monocyclic heterocycle selected from pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and tetrahydropyranyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxy, C₁₋₄alkylcarbonyl, piperidinyl, NR¹²R¹³, C(=O)-O-R¹⁴, R⁶ and C₁₋₄alkyl substituted with one or two substituents independently selected from hydroxy, C₁₋₄alkyloxy, phenyl, C(=O)-O-R¹⁴, -Y-C₁₋₄alkanediyl-C(=O)-O-R¹⁴, R⁶ and NR¹²R¹³;
- Het⁴ represents a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl.
2. A compound as claimed in claim 1 wherein each R⁷ and each R⁸ are independently selected from hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, dihydroxyC₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkylcarbonyl, aminocarbonyl, arylcarbonyl, Het³carbonyl, C₁₋₄alkylcarbonyloxy-C₁₋₄alkylcarbonyl, hydroxyC₁₋₄alkylcarbonyl, C₁₋₄alkyloxy carbonylcarbonyl, mono- or di(C₁₋₄alkyl)aminoC₁₋₄alkyl, arylaminocarbonyl, arylaminothiocarbonyl, Het³aminocarbonyl, Het³aminothiocarbonyl, C₃₋₇cycloalkyl, pyridinylC₁₋₄alkyl, C₁₋₄alkanediyl-C(=O)-O-R¹⁴, -C(=O)-O-R¹⁴, -Y-C₁₋₄alkanediyl-C(=O)-O-R¹⁴, Het³ and R⁶;
- R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl, hydroxy-C₁₋₄alkyl, dihydroxyC₁₋₄alkyl, phenyl, phenylC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkylcarbonyl, aminocarbonyl, phenylcarbonyl, Het³carbonyl,

D²
cont

5 C₁₋₄alkylcarbonyloxyC₁₋₄alkylcarbonyl, hydroxyC₁₋₄alkylcarbonyl, C₁₋₄alkyloxy carbonyl carbonyl, mono- or di(C₁₋₄alkyl)aminoC₁₋₄alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, Het³aminocarbonyl, Het³aminothiocarbonyl, C₃₋₇cycloalkyl, pyridinylC₁₋₄alkyl, C₁₋₄alkanediyl-C(=O)-O-R¹⁴, -C(=O)-O-R¹⁴, -Y-C₁₋₄alkanediyl-C(=O)-O-R¹⁴, Het³ and R⁶; R¹¹ is being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C₁₋₄alkyloxy, formyl, trihaloC₁₋₄alkylsulfonyloxy, R⁶, NR⁷R⁸, C(=O)NR⁷R⁸, -C(=O)-O-R¹⁴, -Y-C₁₋₄alkanediyl-C(=O)-O-R¹⁴, aryl, aryloxy, arylcarbonyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, phthalimide-2-yl, Het³, Het⁴ and C(=O)Het³; and Het² represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazoliny, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, 1H-pyrazolo[3,4-d]-pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo-[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from R¹¹ and C₁₋₄alkyl optionally substituted with one or two substituents independently selected from R¹¹.

25

3. A compound as claimed in claim 1 or 2 wherein the compound of formula (I) contains an ester function.

30

4. A compound as claimed in any one of claims 1 to 3 provided that those compounds wherein X is a direct bond, at least one of R³ and R⁴ is hydrogen, and R² is 3-pyridinyl optionally substituted in the 6 position with an optionally substituted alkyl or acyl group are excluded.

35

5. A compound as claimed in any one of claims 1 to 4 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.

6. A compound as claimed in any one of claims 1 to 5 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl,

sub
B¹

Cont.
Sub B1

5

oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranal, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.

10

7. A compound as claimed in any one of claims 1 to 6 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
8. A compound as claimed in any one of claims 1 to 7 wherein p is 1 or 2 and each R¹ is chloro.

15

9. A compound as claimed in any one of claims 1 to 8 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents, and p is 2 whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.

20

10. A compound as claimed in claim 1 wherein the compound is
- 2-[3,5-dichloro-4-[1-methyl-1-(4-phenyl-2-thiazolyl)ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
- 2-[3,5-dichloro-4-[1-[4-(3-chlorophenyl)-5-methyl-2-thiazolyl]-1-methylethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
- 2-[3,5-dichloro-4-[1-methyl-1-(5-phenyl-1,2,4-oxadiazol-3-yl)ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
- 2-[3,5-dichloro-4-[1-(4,5-diphenyl-2-thiazolyl)-1-methylethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
- 2-[3,5-dichloro-4-[1-methyl-1-[5-(2-methylphenyl)-1,2,4-oxadiazol-3-yl]ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
- 2-[3,5-dichloro-4-[1-methyl-1-(4-methyl-5-phenyl-2-thiazolyl)ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
- 2-[3,5-dichloro-4-[1-methyl-1-[4-phenyl-5-(3-pyridinyl)-2-thiazolyl]ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
- 2-[3,5-dichloro-4-[1-methyl-1-[4-phenyl-5-(phenylmethyl)-2-thiazolyl]ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
- 2-[3,5-dichloro-4-[1-methyl-1-[5-(4-pyridinyl)-1,2,4-oxadiazol-3-yl]ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;

30

35

25
cont


- 2-[3,5-dichloro-4-[1-methyl-1-[4-(3-thienyl)-2-thiazolyl]ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
 2-[3,5-dichloro-4-[1-[4-(2-furanyl)-2-thiazolyl]-1-methylethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
 2-[3,5-dichloro-4-[1-methyl-1-[5-(3-pyridinyl)-1,2,4-oxadiazol-3-yl]ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
 2-[3,5-dichloro-4-[1-methyl-1-[5-(2-methyl-3-pyridinyl)-1,2,4-oxadiazol-3-yl]ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione;
 2-[3,5-dichloro-4-[1-methyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)-dione; a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.

10

11. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in any one of claims 1 to 10.
 12. A process for preparing a composition as claimed in claim 11, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in any one of claims 1 to 10.
 13. A compound as claimed in any one of claims 1 to 10 for use as a medicine.
 14. Use of a compound as claimed in any one of claims 1 to 10 in the manufacture of a medicament for treating eosinophil-dependent inflammatory diseases.
 15. A compound of formula

20


25



wherein R^1 , R^3 , R^4 and p are as defined in claim 1.


16. A process for preparing a compound as claimed in claim 1, characterized by,
 a) reacting an intermediate of formula (II) wherein W^1 is a suitable leaving group with an appropriate reagent of formula (III) optionally in a reaction-inert solvent and optionally in the presence of a base at a temperature ranging between - 70°C and reflux temperature;

30




wherein R², R³, R⁴, p and X are as defined in claim 1;

b) eliminating the group E of a triazinedione of formula (V)




5 wherein E is an appropriate electron attracting group and R¹, R², R⁴, X and p are as defined in claim 1;

c) cyclizing a thioamide of formula (XI-b) with an intermediate of formula (XII) in a suitable solvent



10 wherein W is a suitable leaving group, and R¹, R³, R⁴ and p are as defined in claim 1; thus forming a compound of formula (I-a);

d) reacting an amine derivative of formula (XV-b) with an intermediate of formula R²-W or with a functional derivative thereof in an appropriate solvent



15 wherein W is a suitable leaving group and R¹, R², R³, R⁴ and p are as defined in claim 1;

- and, if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or
5 conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and also, if desired, preparing stereochemically isomeric forms or *N*-oxide forms thereof.
17. A process of marking a receptor comprising the steps of
10 a) radiolabelling a compound as defined in claim 1;
b) administering said radiolabelled compound to biological material,
c) detecting the emissions from the radiolabelled compound.
18. A process of imaging an organ, characterized by, administering a sufficient amount
15 of a radiolabelled compound of formula (I) in an appropriate composition, and detecting the emissions from the radioactive compound.